The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients
Augustinus P. T. van der Ploeg(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), John F. Thompson(Melanoma Institute Australia), Rajmohan Murali(Memorial Sloan Kettering Cancer Center), Alexander C. J. van Akkooi(The University of Sydney), Cornelis Verhoef(Erasmus MC Cancer Institute), Richard A. Scolyer(The University of Sydney), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center)
Cited by 149
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k